Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma

Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma

Failure to predict response to immunotherapy (IO) limited its benefit in the treatment of head and neck squamous cell cancer (HNSCC) to 20% of patients or less. Biomarkers including tumor mutational burden (TMB) and programmed death ligand-1 (PD-L1) were evaluated as predictors of response to IO, bu...

Full description

Bibliographic Details
Main Authors: Kimberly M. Burcher, Jeffrey W. Lantz, Elena Gavrila, Arianne Abreu, Jack T. Burcher, Andrew T. Faucheux, Amy Xie, Clayton Jackson, Alexander H. Song, Ryan T. Hughes, Thomas Lycan, Paul M. Bunch, Cristina M. Furdui, Umit Topaloglu, Ralph B. D’Agostino, Wei Zhang, Mercedes Porosnicu
Format: Article
Language:English
Published: MDPI AG 2021-11-01
Series:Cancers
Subjects:
HNSCC
TMB
immunotherapy
immune checkpoint inhibitors
PD-L1
Online Access:https://www.mdpi.com/2072-6694/13/22/5733

Internet

https://www.mdpi.com/2072-6694/13/22/5733

Similar Items